Skip to main content
. 2023 Jul 14;18(7):e0288598. doi: 10.1371/journal.pone.0288598

Table 4. Difference in change from baseline in quality of life outcomes for the maraviroc + OBT versus OBT group with bootstrapped 95% confidence intervals.

Outcome Week N Difference between MVC+OBT / OBT groups in change from baseline 95% LCL 95% UCL
CLDQ-NAFLD 48 45 -0.3 -1.1 0.4
96 44 -0.5 -1.3 0.2
SF36
Physical function 48 45 -1.7 -11.4 8.1
96 44 -1.0 -11.0 8.9
Role physical 48 44 1.4 -18.0 20.8
96 44 13 -8.9 35.0
Role emotional 48 44 -0.6 -27.3 26.2
96 44 -14.5 -36.0 6.9
Energy/fatigue 48 43 -0.2 -10.4 10.0
96 43 -1.8 -11.9 8.3
Emotional wellbeing 48 43 6.0 -3.4 15.3
96 43 2.6 -7.9 13.1
Social function 48 44 -4.1 -16.0 8.0
96 44 -4.9 -19.2 9.4
Bodily pain 48 43 -1.3 -15.6 12.9
96 43 -7.5 -19.7 4.7
General health 48 45 2.9 -7.1 12.9
96 44 1.5 -7.2 10.3
WPAI:SHP
% Work time missed 48 25 -10.5 -25.6 4.7
96 25 -8.2 -22.8 6.3
% Impairment while working due to NAFLD 48 29 -2.6 -21.3 16.1
96 30 -7.1 -21.0 6.7
% Overall work impairment due to NAFLD 48 25 -5.5 -27.6 16.7
96 25 -13.7 -30.5 3.1
% Activity impairment due to NAFLD 48 43 1.3 -10.3 13.0
  96 43 0.1 -12.4 12.6

LCL, lower confidence interval, UCL upper confidence interval

CLDQ-NAFLD Chronic Liver Disease Questionnaire for NAFLD, SF36 36-item Short Form Survey, WPAI:SHP Work Productivity and Activity Impairment: Specific Health Problem